← Back to Screener
TELA Bio, Inc. Common Stock (TELA)
Price$0.88
Value ScoreB
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-31.39%
Price vs S&P 500 (4W)-13.71%
VGM Score56.74
Market Capitalization$39.40M
All Metrics
Book Value / Share (Quarterly)$0.14
P/TBV (Annual)10.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.68%
Cash Flow / Share (Quarterly)$-0.67
Price vs S&P 500 (YTD)-33.57%
Gross Margin (TTM)67.25%
Net Profit Margin (TTM)-49.30%
EPS (TTM)$-0.80
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-0.80
Revenue Growth (5Y)34.54%
EPS (Annual)$-0.83
ROI (Annual)-62.67%
Gross Margin (Annual)67.69%
Net Profit Margin (5Y Avg)-80.54%
Cash / Share (Quarterly)$0.88
Revenue Growth QoQ (YoY)2.91%
ROA (Last FY)-47.69%
Revenue Growth TTM (YoY)13.48%
EBITD / Share (TTM)$-0.68
ROE (5Y Avg)-294.07%
Operating Margin (TTM)-42.93%
Cash Flow / Share (Annual)$-0.64
P/B Ratio6.24x
P/B Ratio (Quarterly)8.32x
Net Income / Employee (Annual)$-258,900
EV / Revenue (TTM)0.69x
Net Interest Coverage (TTM)-6.36x
ROA (TTM)-56.83%
EPS Incl Extra (Annual)$-0.83
Current Ratio (Annual)4.20x
Quick Ratio (Quarterly)2.76x
3-Month Avg Trading Volume0.21M
52-Week Price Return-54.87%
Revenue / Employee (TTM)$538,800
Tangible BV / Share (Quarterly)$0.11
P/S Ratio (Annual)0.49x
Asset Turnover (Annual)0.99x
52-Week High$2.20
Operating Margin (5Y Avg)-72.98%
EPS Excl Extra (Annual)$-0.83
CapEx CAGR (5Y)21.39%
Tangible BV CAGR (5Y)-36.08%
26-Week Price Return-23.47%
Quick Ratio (Annual)3.40x
13-Week Price Return3.92%
Total Debt / Equity (Annual)8.82x
Current Ratio (Quarterly)3.61x
Enterprise Value$55.72M
Revenue / Share Growth (5Y)3.96%
Asset Turnover (TTM)1.15x
Book Value / Share Growth (5Y)-47.02%
Revenue / Employee (Annual)$535,200
Inventory Turnover (Annual)2.18x
Pretax Margin (Annual)-48.09%
Cash / Share (Annual)$1.14
3-Month Return Std Dev119.15%
Gross Margin (5Y Avg)66.50%
Net Income / Employee (TTM)$-265,600
ROE (Last FY)-615.10%
Net Interest Coverage (Annual)-5.51x
EPS Basic Excl Extra (Annual)$-0.83
Receivables Turnover (TTM)7.97x
Total Debt / Equity (Quarterly)8.82x
EPS Incl Extra (TTM)$-0.80
Receivables Turnover (Annual)7.85x
ROI (TTM)-72.25%
P/S Ratio (TTM)0.49x
Pretax Margin (5Y Avg)-80.53%
Revenue / Share (Annual)$1.71
Tangible BV / Share (Annual)$0.11
Price vs S&P 500 (52W)-79.23%
Year-to-Date Return-25.42%
5-Day Price Return-2.21%
EPS Normalized (Annual)$-0.83
ROA (5Y Avg)-53.94%
Net Profit Margin (Annual)-48.37%
Month-to-Date Return-9.27%
Cash Flow / Share (TTM)$-1.99
EBITD / Share (Annual)$-0.72
Operating Margin (Annual)-43.16%
LT Debt / Equity (Annual)8.82x
ROI (5Y Avg)-68.36%
LT Debt / Equity (Quarterly)8.82x
EPS Basic Excl Extra (TTM)$-0.80
P/TBV (Quarterly)10.61x
P/B Ratio (Annual)8.32x
Inventory Turnover (TTM)2.06x
Pretax Margin (TTM)-49.00%
Book Value / Share (Annual)$0.14
Price vs S&P 500 (13W)-4.33%
Beta1.32x
Revenue / Share (TTM)$1.41
ROE (TTM)-441.55%
52-Week Low$0.50
vGradeB
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.21est. -0.19
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.09
4.09
4.09
4.09
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TELATELA Bio, Inc. Common Stock | B | B | D | $0.88 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
TELA Bio is a medical technology company focused on soft-tissue reconstruction for hernia repair and abdominal wall reconstruction. Its OviTex product portfolio is designed to leverage the body's natural healing response while reducing reliance on permanent synthetic materials. This approach aims to optimize clinical outcomes while preserving patient anatomy.